Caris Life Sciences, Inc.
For the period ended Mar 31, 2026. Filed May 8, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 8, 2026
CAI$25.57+1.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
CARIS LIFE SCIENCES, INC
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
| (amounts in thousands, except share data) | As of March 31, | As of December 31, |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash, cash equivalents, and restricted cash | $821,147 | $797,799 |
| Short-term marketable securities | 2,315 | 2,295 |
| Accounts receivable | 90,517 | 112,140 |
| Supplies | 76,289 | 63,625 |
| Prepaid expenses and other current assets | 23,912 | 21,941 |
| Total current assets | 1,014,180 | 997,800 |
| Property and equipment, net | 82,669 | 63,170 |
| Goodwill | 19,344 | 19,344 |
| Other assets | 46,195 | 45,349 |
| Total assets | $1,162,388 | $1,125,663 |
| Liabilities and Shareholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $69,802 | $39,206 |
| Accrued expenses and other current liabilities | 73,921 | 87,770 |
| Current portion of indebtedness | 173 | 169 |
| Total current liabilities | 143,896 | 127,145 |
| Long-term indebtedness, net of debt discounts | 381,402 | 378,823 |
| Other long-term liabilities | 43,600 | 42,388 |
| Total liabilities | 568,898 | 548,356 |
| Commitments and contingencies (see note 7) | ||
| Shareholders' equity: | ||
| Preferred stock, $0.001 par value per share; 100,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value per share; 2,800,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 284,262,436 and 284,137,810 shares issued as of March 31, 2026 and December 31, 2025, respectively; 282,650,723 and 282,526,097 shares outstanding as of March 31, 2026 and December 31, 2025, respectively; shares issued and outstanding include 23,446 unvested shares subject to repurchase as of March 31, 2026 and December 31, 2025 | 284 | 283 |
| Treasury stock at cost, 1,611,713 shares of common stock as of March 31, 2026 and December 31, 2025 | (16,896) | (16,896) |
| Additional paid-in capital | 3,158,455 | 3,141,720 |
| Accumulated deficit | (2,549,246) | (2,548,736) |
| Accumulated other comprehensive income | 893 | 936 |
| Total shareholders' equity | 593,490 | 577,307 |
| Total liabilities and shareholders' equity | $1,162,388 | $1,125,663 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.